Login to Your Account

Nervous After NovoSeven?

Roche Ending Maxygen Deal For Factor VII Over De-Risk'

By Randall Osborne

Thursday, March 15, 2007
A glitch in the early stage research deep-sixed Maxygen Inc.'s pact with F. Hoffman-La Roche Ltd. for a next-generation Factor VII product, but their older agreement related to finding new compounds for hepatitis B and C viruses continues. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription